Core Viewpoint - Chinese innovative pharmaceutical company Innovent Biologics (01801.HK) announced that its self-developed GCG/GLP-1 dual receptor agonist, Ma Shidu Peptide, achieved its primary endpoint in Phase Ib clinical trials among the adolescent obesity population in China [1] Group 1: Clinical Research Findings - The study showed significant reductions in body mass index (BMI) and weight after 12 weeks of treatment with Ma Shidu Peptide, along with comprehensive improvements in multiple metabolic indicators [1] - The initial results in adolescents mirrored the strong weight loss and metabolic improvement characteristics observed in adult studies, providing a solid scientific basis for further clinical development [1] Group 2: Market Implications - With the ongoing research, Ma Shidu Peptide is expected to address the lack of local innovative drugs for adolescent obesity patients in China [1]
破局“青少年肥胖”难题 信达生物发布最新研究成果